𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dose ratio between morphine and methadone in patients with cancer pain : A retrospective study

✍ Scribed by Peter G. Lawlor; Ken S. Turner; John Hanson; Eduardo D. Bruera


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
87 KB
Volume
82
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Background:

Current equianalgesic reference tables, based largely on single dose studies, give dose ratios of 1:1 to 4:1 for oral morphine to oral methadone, which possibly are inaccurate in patients with cancer pain who are exposed to multiple doses of these opioids. the purpose of this study was to determine the equianalgesic dose ratio between morphine and methadone in patients with cancer pain and to establish whether the dose ratio changes as a function of previous opioid dose.

Methods:

A retrospective analysis of consecutive rotations involving morphine and methadone using standard selection criteria identified a total of 20 evaluable rotations (14 from morphine to methadone and 6 from methadone to morphine). opioid doses and pain intensity levels pre- and postrotation were analyzed.

Results:

Median dose ratios (lower-upper quartiles) for morphine to methadone and methadone to morphine rotations were 11.36 (range, 5.98-16.27) and 8.25 (range, 4.37-11.3), respectively (p = 0.23). combining all 20 rotations, a unified median dose ratio of 11.2 (range, 5.06-13.24) was calculated. there was no significant difference in pain intensity levels pre- and postrotation as recorded on a visual analogue scale. univariate correlational analysis of dose ratio and the level of daily morphine dose prior to rotation revealed a spearman correlation coefficient of 0.86 (p = 0.0001). in patients receiving >1165 mg per day prior to methadone rotation, a median dose ratio of 16.84 (range, 12.25-87.95) was observed, which was approximately 3 times higher compared with a median dose ratio of 5.42 (range, 2.95-9.09) (p = 0.007) for the 50% of patients receiving lower morphine doses.

Conclusions:

The results highlight the general underestimation of methadone potency and the consequent risk of potential life-threatening toxicity. the strongly positive correlation between dose ratio and previous morphine dose suggests the need for a highly individualized and cautious approach when rotating from morphine to methadone in patients with cancer pain.


πŸ“œ SIMILAR VOLUMES


Ultrasound scanning in patients with cli
✍ Daniel Pollock; Kenneth J. W. Taylor πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 418 KB πŸ‘ 1 views

A retrospective study was performed on all patients with clinical suspicion of a pancreatic cancer over a seven-month period. Diagnostic scans of the pancreas were obtained in 87% of the patients. Of 112 patients with a successful ultrasound study, 97 had adequate clinical or surgical follow up. The

Controlled-release morphine tablets in p
✍ Carol A. Warfield πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 143 KB πŸ‘ 2 views

## Background: Controlled-release (cr) morphine tablets have become routine therapy in the management of cancer pain. compared with immediate-release (ir) morphine, this formulation provides the benefit of dosing every 12 hours. ## Methods: This study reviewed the 10 published, well controlled, r

Determining the site of the primary canc
✍ Hirohisa Katagiri; Mitsuru Takahashi; Jiro Inagaki; Hideshi Sugiura; Shigeki Ito πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 61 KB πŸ‘ 1 views

## BACKGROUND. When skeletal metastasis is the presenting problem and the primary site is occult, there is a need to identify the primary site as soon as possible. However, the search for the primary tumor is often time-consuming and difficult. The purpose of this study was to analyze the effica